Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

Share Price is delayed by 15 minutes
Get Live Data
114.00    2.50 (2.24%)
Bid:
112.00
Ask:
116.00
Spread: 4.00 (3.571%)
Market Cap: £68.59m
IGP Live PriceLast checked at - London Stock Exchange

Intraday Intercede Share Chart

Share Buyback Programme

6 Nov 2014 07:00

RNS Number : 2825W
Intercede Group PLC
06 November 2014
 



6 November 2014

 

Intercede Group plc

 

("Intercede" or the "Company")

 

Share Buyback Programme

 

 

Intercede announces its intention to commence a share buyback programme (the "Buyback Programme") to acquire up to 250,000 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") as and when they become available at volumes and prices that, from time to time, the Board considers appropriate.

The Board intends that any Ordinary Shares acquired pursuant to the Buyback Programme will be held in treasury and used in relation to staff incentive schemes. Any shares acquired pursuant to the Buyback Programme will be immediately notified to a Regulatory Information Service in accordance with the AIM Rules for Companies.

Any acquisitions will be effected in accordance with the Company's general authority to buy back Ordinary Shares and within certain set parameters, including that the maximum price paid per Ordinary Share is to be no more than 105% of the average middle market price of an Ordinary Share for the five business days preceding the date of acquisition.

In addition, given the liquidity in the Ordinary Shares, the Company may buy back in any one day more than 25% of the average daily volume over the preceding 20 business days.

Intercede confirms that it currently has no unpublished price sensitive information.

 

ENQUIRIES

 

Intercede Group plc

Tel. +44 (0)1455 558111

Andrew Walker, Finance Director

finnCap

Tel. + 44 (0)20 7220 0500

Stuart Andrews, Corporate Finance

Joanna Weaving, Corporate Broking

 

About Intercede

Intercede is a software company specialising in identity and credential management with a global team of experts located in the US and UK.

Intercede's MyID software enables organisations to create and use trusted digital identities for employees, citizens and machines. This allows secure access to services, facilities, information and networks.

MyID meets the highest government standards yet is simple enough to be deployed onto consumer devices such as smart phones and tablets. Critically, MyID provides an easy, convenient and secure alternative to passwords.

Millions of identities are managed using MyID and Intercede has provided identity verification and management services to global customers for more than 20 years. MyID is a commercial off the shelf software product, designed and developed to be configurable so it can be embedded as the cornerstone of cyber security infrastructure for governments and corporations.

Customers trusting Intercede for secure digital identity include the US and UK governments and some of the world's largest corporations, telecommunications providers and information technology partners.

For more information about Intercede, please visit www.intercede.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCQKPDDFBDDNDK
Date   Source Headline
20th Jul 20217:00 amRNSIntercede achieves FIDO2 certification
5th Jul 20217:00 amRNSConnect Partner Programme & Q1 Contract Wins
15th Jun 20218:26 amRNSIssue of Equity
8th Jun 20217:00 amRNSFinal Results
2nd Jun 202110:09 amRNSInvestor Presentation
10th May 20217:00 amRNSShare Incentive Plan
7th Apr 20217:00 amRNSTrading Update & Appointment of Auditor
1st Apr 202110:30 amRNSReceipt of $3.4m Order
10th Mar 20217:00 amRNSShare Incentive Plan
23rd Feb 20217:00 amRNSAmendment to LTIP
22nd Feb 20214:10 pmRNSHolding(s) in Company
16th Feb 20217:00 amRNSCLN Conversion to Equity
12th Feb 20217:00 amRNSHolding(s) in Company
8th Feb 202112:40 pmRNSHolding(s) in Company
4th Feb 20217:00 amRNSCLN Call & Issue of Equity
11th Jan 20217:00 amRNSNew Contract Win
5th Jan 202111:00 amRNSCLN Conversion to Equity
4th Jan 202110:40 amRNSHolding(s) in Company
22nd Dec 20207:00 amRNSNew Contract Win
24th Nov 20207:00 amRNSHalf-year Report
17th Nov 20207:00 amRNSContract Win: Follow-on Purchase Order
12th Nov 20207:00 amRNSInvestor Presentation
8th Oct 20207:01 amRNSIntercede join the FIDO Alliance
8th Oct 20207:00 amRNSTrading Update
16th Sep 20203:40 pmRNSResult of AGM
20th Aug 20207:05 amRNSContract Win - Initial Progress Order
5th Aug 20202:01 pmRNSHolding(s) in Company
30th Jul 20207:00 amRNSContract Win
2nd Jun 20207:00 amRNSFinal Results
12th May 20207:00 amRNSShare Incentive Plan
20th Apr 202010:02 amRNSDirector/PDMR Shareholding
14th Apr 20207:00 amRNSDirector/PDMR Shareholding
7th Apr 20207:00 amRNSTrading Update
3rd Apr 20205:07 pmRNSShare Incentive Plan
31st Mar 20207:00 amRNSReceipt of $4.6m Order
28th Feb 20207:00 amRNSShare Incentive Plan
26th Feb 20209:50 amRNSShare Incentive Plan
25th Feb 20207:00 amRNSShare Incentive Plan
12th Feb 202011:22 amRNSShare Award
25th Nov 20197:00 amRNSHalf-year Report
7th Oct 20197:00 amRNSTrading Update
30th Sep 20197:00 amRNSDirector/PDMR Shareholding
18th Sep 20196:30 pmRNSResult of AGM
16th Sep 20193:56 pmRNSPosting of Annual Report & Notice of AGM
17th Jun 20197:00 amRNSAppointment of Non-Executive Director
5th Jun 20197:00 amRNSFinal Results
8th Apr 20197:00 amRNSSale of Property
2nd Apr 20197:00 amRNSTrading Update
28th Feb 20197:00 amRNSNew Contract Win
4th Feb 20193:19 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.